European Commission logo
English English
CORDIS - EU research results
Content archived on 2024-05-14

Towards a novel generation of immunotherapeutics for Type-I allergies


Atopic allergic diseases affect a constantly increasing segment of the population. At present, treatments are mostly confined to symptomatic drug regimens. Allergen-driven desensitization programs are used with moderate success. Any innovative form of immunotherapy for Type-I allergies should therefore be aimed at the interference with the underlying immunological mechanisms. The aim of the present research project is to develop a targeting technology to significantly improve immunotherapy using chemically modified allergens. For this, we will use our recent patented discovery that targeting of antigen to antigen presenting cells via Fc-receptor (FcR) bridging results in disabled presentation of the antigen and in antigen-specific inactivation of T cells. This should lead to a better and safer treament modality for Type-I allergies.

Call for proposal

Data not available


Pangenetics BV
EU contribution
No data
1105 BE Amsterdam

See on map

Total cost
No data

Participants (1)